Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1179/acb.2001.052 http://scihub22266oqcxt.onion/10.1179/acb.2001.052 11881319!ä!11881319 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Clin+Belg 2001 ; 56 (6): 349-53 Nephropedia Template TP {{tp|p=11881319|t=2001. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium |pdf=|usr=}}{{11881319}} gab.com Text In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium JO: Acta Clin Belg http://www.kidney.de/pget.php?&tw=1&pmid=11881319 #FOAvip In Belgium more than 17% of the invasive pneumococci are not susceptible to penicillin, and more than 38% not to macrolides. The most prevalent mechanism of macrolide resistance in Europe is modification of the drug target site leading to cross-resistance to lincosamides and group B streptogramines (MLSB resistance). Telithromycin is the first antibiotic of the family of ketolides, which differ from erythromycin by having a 3-keto group instead of the neutral sugar L-cladinose. We tested the susceptibility of 637 pneumococci, recently isolated from patients in Belgium, to telithromycin and five other antibiotics. Data generated by this study show that telithromycin inhibits 98.4% of pneumococci at a breakpoint concentration of 1 mg/L in spite of a high percentage (> 30%) of strains with the MLSB constitutive type of resistance. Susceptibilities to the five comparator drugs were: penicillin (81.8%), tetracycline (67.0%), levofloxacin (98.9%), erythromycin (61.5%) and clindamycin (66.6%). Consequently telithromycin looks to have considerable potential for the empiric treatment of community-acquired respiratory tract infections. Twit Text FOAVip In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium ????Acta Clin Belg http://www.kidney.de/pget.php?&tw=1&pmid=11881319 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=11881319 #FOAvip English Wikipedia <ref>{{Cite pmid|11881319}}</ref> In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium #MMPMID11881319 Verhaegen J; Verbist L Acta Clin Belg 2001[Nov]; 56 (6): 349-53 PMID11881319show ga In Belgium more than 17% of the invasive pneumococci are not susceptible to penicillin, and more than 38% not to macrolides. The most prevalent mechanism of macrolide resistance in Europe is modification of the drug target site leading to cross-resistance to lincosamides and group B streptogramines (MLSB resistance). Telithromycin is the first antibiotic of the family of ketolides, which differ from erythromycin by having a 3-keto group instead of the neutral sugar L-cladinose. We tested the susceptibility of 637 pneumococci, recently isolated from patients in Belgium, to telithromycin and five other antibiotics. Data generated by this study show that telithromycin inhibits 98.4% of pneumococci at a breakpoint concentration of 1 mg/L in spite of a high percentage (> 30%) of strains with the MLSB constitutive type of resistance. Susceptibilities to the five comparator drugs were: penicillin (81.8%), tetracycline (67.0%), levofloxacin (98.9%), erythromycin (61.5%) and clindamycin (66.6%). Consequently telithromycin looks to have considerable potential for the empiric treatment of community-acquired respiratory tract infections. |*Ketolides[MESH] |*Macrolides[MESH] |Anti-Bacterial Agents/*pharmacology[MESH] |Belgium/epidemiology[MESH] |Drug Resistance, Microbial[MESH] |Humans[MESH] |Microbial Sensitivity Tests[MESH] |Sensitivity and Specificity[MESH] |Streptococcal Infections/drug therapy/epidemiology[MESH]In vitro activity of the new ketolide telithromycin and other antibiot(epmc).pdf DeepDyve Pubget Overpricing